Sapropterin (generic) (Sapropterin Dihydrochloride TABLET) 100 mg/1

Sapropterin dihydrochloride is an oral medication approved by the FDA as an orphan drug for the treatment of phenylketonuria (PKU), a rare inherited metabolic disorder. It belongs to the endocrinology and metabolic disorder therapeutic category. Sapropterin works by enhancing the activity of the phenylalanine hydroxylase enzyme, helping to reduce elevated blood phenylalanine levels in responsive patients.

Strength

100 mg/1

Pack Size

120 TABLET in 1 BOTTLE (0054-0906-23)

Manufacturer / TM Owner

Generic

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Sapropterin is indicated for the treatment of hyperphenylalaninemia in patients with phenylketonuria (PKU) who have residual phenylalanine hydroxylase (PAH) activity. PKU is a rare autosomal recessive metabolic disorder characterized by deficiency of the PAH enzyme, leading to accumulation of phenylalanine and its metabolites, which can cause severe neurological damage, intellectual disability, and developmental delays if untreated. Sapropterin is a synthetic form of tetrahydrofolate (BH4), a natural cofactor that enhances PAH enzyme function in patients with certain PAH mutations. The drug is used in patients diagnosed with BH4-responsive PKU, typically identified through genotyping or responsiveness testing. Treatment with sapropterin allows eligible patients to maintain lower blood phenylalanine concentrations, potentially reducing dietary restrictions and improving quality of life. The medication is particularly beneficial for patients who cannot adequately control phenylalanine levels through diet alone or who have difficulty adhering to restrictive protein-limited diets.

Side Effects

Common side effects of sapropterin include headache, rhinitis, pharyngitis, diarrhea, vomiting, and cough. Some patients may experience abdominal pain, nausea, or upper respiratory tract infections. Serious adverse events are rare but may include hypersensitivity reactions. Regular monitoring of blood phenylalanine levels is essential to assess treatment efficacy and adjust dosing accordingly. Patients should have baseline and periodic assessments of renal function and blood pressure. Ophthalmologic examination may be recommended, as BH4 can affect certain eye conditions. Blood phenylalanine concentrations should be monitored regularly, typically every 1-2 weeks initially, then monthly once stable, to ensure therapeutic goals are maintained and prevent complications.

Precautions & Warnings

Sapropterin is contraindicated in patients with known hypersensitivity to sapropterin or any excipients. Use with caution in patients with hepatic or renal impairment, as dose adjustments may be necessary. The drug should not be used in patients with non-PKU hyperphenylalaninemia or secondary hyperphenylalaninemia. Pregnancy category C; use only if benefits justify potential risks to the fetus. Pediatric patients can receive sapropterin, but dosing should be weight-based and carefully monitored. Patients with seizure disorders or those taking medications that lower seizure threshold require careful monitoring. Individuals with certain ophthalmologic conditions, including retinal disorders, should be evaluated before initiating therapy. Regular assessment of treatment response is critical, as not all PKU patients respond to sapropterin therapy.

Avoid Interactions

Sapropterin may interact with medications that affect folate metabolism or phenylalanine levels. Concurrent use with levodopa should be avoided due to potential competitive inhibition. Medications affecting renal function may alter sapropterin clearance. Dietary supplements containing phenylalanine or large neutral amino acids may reduce sapropterin efficacy. Patients should maintain consistent dietary protein intake and avoid sudden changes in phenylalanine consumption. Consultation with a metabolic specialist is recommended before initiating concurrent medications, particularly those affecting neurotransmitter synthesis or renal function.

Frequently Asked Questions

Sapropterin is used to treat phenylketonuria (PKU), a rare inherited metabolic disorder caused by deficiency of the phenylalanine hydroxylase enzyme. It works by enhancing enzyme activity in patients with BH4-responsive PKU, helping to lower blood phenylalanine levels. This reduces the need for strict dietary restrictions and helps prevent neurological complications associated with elevated phenylalanine.

Sapropterin is administered orally as a tablet that is typically dissolved in water or apple juice before ingestion. The standard starting dose is 10 mg/kg once daily, with adjustments based on blood phenylalanine response and tolerability. Dosing is individualized and should be determined by a metabolic specialist experienced in PKU management.

Common side effects include headache, rhinitis, pharyngitis, diarrhea, vomiting, and cough. Most side effects are mild to moderate and tend to decrease with continued use. Serious adverse events are uncommon, but patients should report any unusual symptoms or allergic reactions to their healthcare provider.

Sapropterin is available as a generic medication from multiple manufacturers. Originally developed and marketed as Kuvan by BioMarin Pharmaceutical, generic versions are now produced by various pharmaceutical companies.

Yes, sapropterin received FDA orphan drug designation for the treatment of phenylketonuria due to PKU's rarity and the significant unmet medical need in this patient population. Orphan drug status provides incentives for development and commercialization of treatments for rare diseases affecting fewer than 200,000 people in the United States.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.